tbuckley/cabot-search huggingface dataset:
AB0845 Technetium-99 conjugated with methylene diphosphonate ameliorates glucocorticoid induced osteoporosis in rats
Authors: L Shi, Y Ning, J Li, F Hu, X Zhang
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> <sup>99</sup>Tc-MDP has been used in Chinese RA patients for over 15 years and many more studies have focused on this agent in RA. However, the previous studies limited in its effect on the effects of anti-inflammation. As a special form of bisphosphonate, the anti-osteoporotic effect of <sup>99</sup>Tc-MDP is unclear. <h3>Objectives</h3> To systematically investigate the effect of technetium-99 conjugated with methylene diphosphonate (<sup>99</sup>Tc-MDP), an anti-inflammatory drug effective in treating rheumatoid arthritis (RA), on cortical and cancellous bones in glucocorticoid-induced osteoporotic (GIO) rats, as well as comparing the effect of <sup>99</sup>Tc-MDP with that of methylene diphosphonate (MDP). <h3>Methods</h3> Forty-eight Sprague-Dawley rats were randomly divided into six groups: blank, negative control, high dose, medium dose, low dose, and positive control groups. After dexamethasone was given to all groups except the blank group to induce osteoporosis, the rats in different groups were treated with saline, MDP, or different doses of <h3>Results</h3> Micro-CT analyses showed that: (1) <sup>99</sup>Tc-MDP reversed glucocorticoid induced bone microarchitecture destruction by increasing vBMD, BV/TV, Tb.Th, Tb.N and decreasing BS/BV, Tb.Sp and TBPf; (2) effect of <sup>99</sup>Tc-MDP increased as its dosage increased; and (3) <sup>99</sup>Tc-MDP could improve cortical bone thickness while MDP failed to do so. Micro-CT spatial structure analysis and histology also yielded consistent results, indicating <sup>99</sup>Tc-MDP increased trabecular number and connectivity morphologically. Finally, biomechanics revealed <sup>99</sup>Tc-MDP can enhance the extrinsic stiffness of bone by changing bone geometry. <h3>Conclusions</h3> <sup>99</sup>Tc-MDP has anti-osteoporotic effect by improving both cancellous and cortical bone, as well as increasing extrinsic bone stiffness. The dual effect of <sup>99</sup>Tc-MDP, anti-inflammatory and anti-osteoporotic, may suggest a potential clinical application for patients with both GIO and RA. <h3>References</h3> Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nature reviews Rheumatology 2010;6:693–702. Bijlsma JW. Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012;51 Suppl 4:iv9–13. <h3>Acknowledgements</h3> We thank Mr. Kai Gao for providing the rats and Dr. Min Feng for assistance in histological processing of the rats. This work was supported by grants from the Natural Science Foundation of China (81501396 to Dr. Lianjie Shi, and 81302554 to Dr. Fanlei Hu). <h3>Disclosure of Interest</h3> None declared
Abstract 20033: Periodontal Disease Activity Independently Predicts Future Risk for Cardiovascular Events
Authors: Amorina Ishai, Richard Takx, Ali Abdelrahman, Karim ElKholy, Thomas Van Dyke, Ahmed Tawakol
Journal: Circulation (2016)

Background: While several lines of evidence show a link between periodontal disease (PD) and cardiovascular disease (CVD), the independence of this association is still debated and the mechanisms m...
AB0516 Incidence of cancer in a cohort of patients with primary sjÖgren syndrome
Authors: M Brom, S Moyano, M Scolnik, LE Pompermayer, IJ Gandino, ER Soriano
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The most severe complication of Sjögren Syndrome is the development of lymphoproliferative processes. Several neoplasia have been associated with the disease, being non-Hodgkin lymphoma the most frequent one. <h3>Objectives</h3> Our objective was to evaluate incidence of cancer in a cohort of patients with primary Sjögren Syndrome. <h3>Methods</h3> A retrospective descriptive study was performed in a university hospital with its own health insurance and captive population. Using electronic medical records and laboratory database were review the entries performed between 01/01/2000 and 12/31/2015. We analyzed those patients with either diagnosis of Sjögren Syndrome, complain of dry mouth/eyes, or positive antibodies anti-Ro/SSA and anti-LA/SSB. Among these patients, we included those fulfilling either ACR 2012 or EULAR 2002 Sjögren criteria, or those who were diagnosed as Primary Sjögren Syndrome by the treating rheumatologist even if they did not fulfill criteria. We then proceeded to register and analyze demographic, clinical and histopathologic information available on their clinical records. <h3>Results</h3> One hundred fifty-seven patients with Primary Sjögren Syndrome were identified. Female accounted for 95.5% of the cohort; mean age at diagnosis was 49.4 years (SD 19). Median follow-up time was 7.7 years (IQR 8). The development rate and type of neoplasia was the following: Lymphomas: Three (Two MALT lymphomas of the parotid and one disseminated non-Hodgkin lymphoma). Density of Incidence 260/100,000 person/year (CI 95%: 50 – 750/100,000 person/year) Multiple Myeloma: One Skin (non-melanoma) neoplasia: Four Solid organ Neoplasia: Seven (Four breast cancer, one lung cancer, one uterus cancer, one tongue cancer). Density of Incidence 600/100,000 person/year (CI 95% 240 – 1240/100,000 person/year) Univariate analysis showed association between lymphoma and cryoglobulinemia (p=0.01; OR=5,8), low C4 fraction of complement (p=0.01; OR=5,1), anemia (p=0.02; OR=1,96) and leucopenia (p=0.03; OR=1,67) <h3>Conclusions</h3> Development of cancer is a known complication of Primary Sjögren Syndrome. The association between lymphoma and cryoglobulinemia, low C4 fraction of complement, anemia and leucopenia enhances the importance of periodic screening for neoplasms among this subgroup of patients with Primary Sjögren Syndrome. <h3>Disclosure of Interest</h3> None declared
Current status and strategies for the control of viral hepatitis A in Korea
Authors: Eileen L. Yoon, Dong Hyun Sinn, Hyun Woong Lee, Ji Hoon Kim
Journal: Clinical and Molecular Hepatology (2017)

Hepatitis A virus is one of the most frequent causes of foodborne infection, which is closely associated with sanitary conditions and hygienic practices. The clinical spectrum of acute hepatitis A is wide, ranging from mild case without any noticeable symptoms to severe case with acute liver failure leading to mortality. The severity and outcome are highly correlated with age at infection. In developing countries, most people are infected in early childhood without significant symptom. Ironically, in area where sanitary condition has improved rapidly, adults who do not have immunity for viral hepatitis A (VH-A) in early childhood is accumulating. Adults without immunity are exposed to risks of symptomatic disease and large outbreaks in society. In Korea, where hygiene has improved rapidly, acute hepatitis A is a significant health burden that needs to be managed with nationwide health policy. The incidence of symptomatic VH-A has increased since 2000 and peaked in 2009. Korea has designated hepatitis A as a group 1 nationally notifiable infectious disease in 2001. Since 2001, mandatory surveillance system has been established to detect every single case of acute hepatitis A. Universal, nationwide vaccination program for newborns was introduced in 2015. In this review, we will present the current epidemiologic status of viral hepatitis A, and evaluate the effectiveness of the current nationwide strategies for the control of viral hepatitis A in Korea. Furthermore, we presented some action proposals that can help eliminate viral hepatitis A, which is a significant health burden in Korea. Keywords: Hepatitis A; Vaccination; Strategy; Korea
SAT0565 The frequency of septic arthritis after arthrocentesis and intra articular glucocorticoid injection is low
Authors: SK Petersen, RA Andreasen, IMJ Hansen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Intraarticular (IA) procedures have both diagnostic and therapeutic purposes in patients with arthritis. The therapeutic benefit of IA glucocorticoids (GC) injection in patients with rheumatologic diseases is well described. However, IA procedures are associated with increased risk of Septic arthritis (SA). Rapid diagnose and correct treatment is crucial to avoid joint damage, sepsis and potential fatal outcome. However, patients in risk of evolving SA secondarily to GC injection or arthrocentesis are not well defined. <h3>Objectives</h3> The aim of this study was to evaluate the risk of SA in patients who received an IA GC injection or an isolated joint puncture, and to describe possible characteristics for these patients. <h3>Methods</h3> All patients9 undergoing IA procedures at the orthopaedic and rheumatological departments of Fuhnen from January 2006 to December 2013 were identified in the central database and included by register extraction. Patients who developed SA within 30 days after IA GC injection were registered as cases. SA was defined as clinically inflamed joint and positive synovial fluid culture. Retrospectively, data on age, gender, affected joint location, bacterial agent, pre-existing inflammatory disorder and death within 30 days were extracted from the patient files. According to local recommendations a non-touch sterile technic where used for IA procedures. Patients were informed about the risk for SA and motivated to seek medical attention if suspicion of infection or lack of improvement. <h3>Results</h3> 22370 IA procedures were registered; 14118 IA GC injections and 8252 arthrocentesis. Eleven patients with SA were registered. Eleven patients developed SA subsequently to IA GC injection (0.08% of all GC injections). For patients9 demography, joint distribution, bacterial agent and pre-excisting joint disease (Table 1). One patient died within 30 days after IA GC injection. <h3>Conclusions</h3> This study demonstrates that IA procedures can be performed with little risk of SA. The risk factors identified i.e. elderly patients with inflammatory joint diseases are consistent with those described in the literature [1]. We consider joint puncture technique and patient information for being essential when doing IA procedures. However, if SA occurs it is potentially fatal and therefore GC injection should be preserved for doctors with experience in joint diseases. <h3>References</h3> RA Andreasen et al. Prognostic factors associated with mortality in patients with septic arthritis: a descriptive study. Scand J Rheumatoly 2016, 1–6. <h3>Disclosure of Interest</h3> None declared
Maintenance of the MnSOD-mediated delayed radioprotective effect in human microvascular endothelial cells by repeated administration of amifostine's active metabolite WR1065
Authors: Jeffrey S. Murley, Danupon Nantajit, Yasushi Kataoka, David J. Grdina
Journal: Cancer Research (2006)

577   The development of chemical compounds to protect against radiation damage has centered on thiol-containing free radical scavenging agents. To be effective these agents must be administered shortly before radiation exposure at their maximum tolerated dose. The most effective radioprotective drug that has been developed to date and the only agent that is approved by the FDA for use in the protection of normal tissues in patients being treated with radiation is amifostine. We recently identified a new radioprotection paradigm for WR1065, amifostine9s active thiol metabolite, which we termed the delayed radioprotective effect. The mechanism for this protection involves the ability of WR1065 to activate the transcription factor NFκB, enhance manganese superoxide dismutase ( MnSOD ) gene expression, and to significantly elevate active MnSOD enzyme levels in cells. Protection against cell killing was observed for cells irradiated 24 h after drug treatment, the timeframe during which the maximum elevation in MnSOD levels was observed. The magnitude of the delayed protection was equal for cells treated with 4 mM (cytoprotective dose) or 40 μM (non-cytoprotective but anti-mutagenic dose) WR1065, and was comparable to that observed for cells irradiated in the presence of 4 mM WR1065 at the clinically relevant radiation dose of 2 Gy. To determine whether this delayed radioprotective effect could be maintained for a prolonged period of time, human microvascular endothelial cells (HMEC) were treated with 40 μM WR1065 using three administration protocols: (1)Daily drug exposure followed by irradiation with 2 Gy 24 h later, (2) Drug exposure every 48 h followed by irradiation with 2 Gy 48 h later, or (3) Drug exposure every 72 h followed by irradiation with 2 Gy 72 h later. Under the first experimental protocol, significant WR1065-induced protection against cell killing was observed over the entire treatment period (average protection factor = 1.36). Treatment with WR1065 every other day also induced significant protection of cells irradiated with 2 Gy 48 h later (protocol 2) (average protection factor = 1.23). No delayed protection was observed when cells were treated with WR1065 every 72 h and irradiated three days later (protocol 3) (average protection factor = 1.09). The ability of WR1065 to induce a delayed radioprotective effect when administered every 24 - 48 h correlates with the elevation in MnSOD enzyme levels we have previously observed following a single drug exposure. These observations may have important implications in the field of radiation oncology and radioprotection in general. This work was supported by NIH/NCI grant R01 CA99005 and DOE grant DE-FG02-05ER64086 (D.J.G.).
AB1196-HPR A comparison of patient preference and usability between two electronic goniometric gloves in the measurement of joint movement in patients with rheumatoid arthritis
Authors: D Small, PV Gardiner, J Connolly, J Condell, K Curran, A O'Neill, R Friel
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with Rheumatoid arthritis suffer from pain, stiffness and reduced mobility of their finger joints. Instrumented electronic goniometric gloves have been developed which can enable dynamic measurements to be made with accuracy and efficiency [1]. This technology could be employed in assessing patients with rheumatoid arthritis and could also be used as an aid to rehabilitation. However, pain and swelling in the joints might limit the applicability of these measurement devices as to date they have not been tested in this patient group. <h3>Objectives</h3> The purpose of this pilot study was to establish the usability of two different electronic gloves in patients with mild to moderate Rheumatoid arthritis. We wished to establish if patients experienced difficulty donning or doffing either glove or if carrying out a series of measurements with the gloves on caused a change in pain and stiffness. We also investigated differences in the usability and preference between the two Datagloves. <h3>Methods</h3> We compared a commercially available electronic glove (the 5DT dataglove 14 Ultra) with a bespoke IMU based electronic glove produced to our specifications by Tyndall National Institute, University College Cork (Figure). We developed a programming interface for both devices to facilitate calibration and detailed evaluation of joint movement. Nine patients with mild to moderate rheumatoid arthritis who were experiencing significant but not severe pain and early morning stiffness in their hands were recruited. After calibration, the patients worked through a protocol of finger flexion and extension movements, which were repeated for each glove and again to test repeatability. The patients completed questionnaires before and after using the gloves on their pain and stiffness levels and at the end of the session on glove donning and doffing usability and preference between the two gloves. <h3>Results</h3> All nine patients were able to don and doff the IMU glove without any difficulty compared to 4/9 for the 5DT glove. Seven of 9 patients expressed a preference for the IMU glove. In 2/9 patients, joint stiffness increased after using the gloves and 4/9 patients reported an increase in pain. Seven out of nine patients were not able to complete the fourth set of movement tests because of discomfort. <h3>Conclusions</h3> Electrogoniometric gloves are usable in patients with rheumatoid arthritis, but patients cannot tolerate longer protocols without an increase in discomfort. <h3>References</h3> Dipietro L, et al. (2003). Evaluation of an instrumented glove for hand-movement acquisition. Journal of Rehabilitation Research and Development, 40(2), 179–89. <h3>Disclosure of Interest</h3> None declared
US drug maker sues to force Ireland to offer expensive Duchenne’s treatment
Authors: Owen Dyer
Journal: BMJ (2017)

The American pharmaceutical firm PTC Therapeutics is suing Ireland’s Health Service Executive (HSE) over its decision not to fund drugs for two boys with Duchenne muscular dystrophy (DMD).

PTC’s drug, ataluren (Translarna), has been approved by the European Medicines Agency (EMA) to treat the nonsense mutation form of DMD in children aged over 5. This condition affects two boys over 5 in the Republic of Ireland and one in Northern Ireland. The boy in Northern Ireland is receiving the drug and has benefited, according to his parents. The two boys …
FRI0488 Psoriatic arthritis in the united states: increasing all-cause hospitalizations 1993–2014
Authors: G Singh, C Moise, A Mithal, R Ionescu, A Mithal
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Psoriatic arthritis (PsA) is a rare disease, with an estimated prevalence of 0.02 – 0.42% in Europe and US (1). PsA is often regarded as a mild disease, but recent data suggest an increase in comorbidities and mortality, possibly related to systemic inflammation (1). <h3>Objectives</h3> To study all-cause hospitalizations in patients with PsA in the United States (US) from 1993 to 2014. <h3>Methods</h3> The Nationwide Inpatient Sample (NIS) is a stratified random sample of all US community hospitals. It is the only US national hospital database with information on all patients, regardless of payer, including persons covered by Medicare, Medicaid, private insurance, and the uninsured. We examined all inpatient hospitalizations in NIS from 1993 to 2014 with a primary or secondary diagnosis of PsA, and compared them to total all-cause US hospitalizations during the same period. US population estimates and projections for the resident US population were obtained from the US Census Bureau. <h3>Results</h3> There were 789.8 million all-cause hospitalizations in 6.4 billion person-years of observation from 1993 to 2014 (123.4 hospitalizations per 1,000 person-years). During this time-period, 332,496 hospitalizations occurred in patients with PsA (5.2 per 100,000 person-years). All-cause US hospitalizations increased from 33.7 million in 1993 to 35.4 million in 2014, an increase of 4.8% over 22 years (Figure, dotted blue line). All-cause hospitalizations in PsA patients have increased from 6,866 in 1993 (2.6 per 100,000 person-year) to 33,875 in 2014 (10.6 per 100,000 person-years, a dramatic increase of over 393% (p&lt;0.0001, Figure solid red line). In 2014, hospitalizations in PsA patients accounted for 163,630 hospital days at a total national cost of over US$1.66 billion. <h3>Conclusions</h3> All-cause hospitalizations in patients with PsA in the US have significantly increased by 393% in the last 22 years, almost 80-fold of the 4.8% increase in US population all-cause hospitalization rate in the same time-period. This calls for an increase need for identification and management of serious co-morbid conditions in patients with PsA. <h3>References</h3> J Gelfand, D Gladman et al. Epidemiology of Psoriatic Arthritis in the Population of the United States. J Am Acad Dermatology, vol 53, p 573–577. <h3>Disclosure of Interest</h3> None declared
A H<sub>2</sub>O<sub>2</sub>-Responsive Theranostic Probe for Endothelial Injury Imaging and Protection
Authors: Cheng-Kun Wang, Juan Cheng, Xing-Guang Liang, Chao Tan, Quan Jiang, Yong-Zhou Hu, Ying-Mei Lu, Kohji Fukunaga, Feng Han, Xin Li
Journal: Theranostics (2017)

Overproduction of H 2 O 2 causes oxidative stress and is the hallmark of vascular diseases.Tracking native H 2 O 2 in the endothelium is therefore indispensable to gain fundamental insights into this pathogenesis.Previous fluorescent probes for H 2 O 2 imaging were generally arylboronates which were decomposed to emissive arylphenols in response to H 2 O 2 .Except the issue of specificity challenged by peroxynitrite, boric acid by-produced in this process is actually a waste with unknown biological effects.Therefore, improvements could be envisioned if a therapeutic agent is by-produced instead.Herein, we came up with a "click-to-release-two" strategy and demonstrate that dual functional probes could be devised by linking a fluorophore with a therapeutic agent via a H 2 O 2 -responsive bond.As a proof of concept, probe AP consisting of a 2-(2'-hydroxyphenyl) benzothiazole fluorophore and an aspirin moiety has been prepared and confirmed for its theranostic effects.This probe features high specificity towards H 2 O 2 than other reactive species including peroxynitrite.Its capability to image and ameliorate endothelial injury has been verified both in vitro and in vivo.Noteworthy, as a result of its endothelial-protective effect, AP also works well to reduce thrombosis formation in zebrafish model.
SAT0576 Improved clinical scenario for chikungunya diagnosis
Authors: JC Rueda, J-I Angarita, AM Santos, E-L Saldarriaga, I Pelaez-Ballestas, MJ Soares-Santeugini, J Londono
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The World Health Organization (WHO) criteria for chikungunya virus infection (CHIKV) have a specificity of 91,1% with a low sensibility of 56,2%, which decreases the ability to detect patients with the infection. Because of this issue a group of rheumatology, epidemiology and bacteriology experts in diagnosing and treating CHIKV patients performed an agreement consensus on the clinical characteristics of CHIKV infection and proposed a set of clinical criteria. In order to test the performance of the new criteria and improve sensibility and specificity a clinical scenario was developed with the agreements from the expert panel and the clinical characteristics with higher odds ratios. <h3>Objectives</h3> To improve sensibility and specificity of a set of clinical criteria for the diagnosis CHIKV. <h3>Methods</h3> Odds ratios of the clinical features of patients with CHIKV infection were analysed. A clinical scenario was developed and sensitivity and specificity was calculated. <h3>Results</h3> 37 clinical characteristics were evaluated in a cohort of 604 patients with suspicion of CHIKV. From those, 29 exhibited statistical significance and only 10 had high odds ratios (table 1). A clinical scenario with the following joint involvement (symmetrical arthritis of shoulders or wrists or hands or knees or ankles or feet) or systemic symptoms (fever or rash or myalgia or fatigue) poised a sensitivity of 74,2% (PPV: 83,5%) and a specificity of 88,4% (NPV: 81,2%). The following clinical characteristics extracted from the agreements of the consensus group were added to the clinical picture: origin from an epidemic area and abrupt onset of symptoms. <h3>Conclusions</h3> Our study demonstrated that the proposed clinical scenario for suspicion of CHIKV improves diagnostic sensibility with a slight decrease in specificity, increasing the chance of diagnosis without the need for laboratory tests. We propose that a patient from an epidemic area (fulfilling epidemiological criteria according to the WHO) with an abrupt onset of a clinical picture of symmetrical arthritis of any of the following joints: hands, wrists, shoulders, knees or feet, or the presence of any of the following systemic symptoms: fever, rash, fatigue or myalgia, is more likely to have CHIKV infection. <h3>Disclosure of Interest</h3> None declared